vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2023-1-90-98vtio-1569Research ArticleТрансплантация сердца и вспомогательное кровообращениеHeart Transplantation and Assisted CirculationМеханическая поддержка кровообращения у детей: патофизиология педиатрического гемостаза и алгоритмы послеоперационного веденияPediatric mechanical circulatory support: pathophysiology of pediatric hemostasis and postoperative management algorithmsКолосковаН. Н.KoloskovaN. N.

Колоскова Надежда Николаевна - заведующая отделением кардиологии в ФГБУ НМИЦ ТИО им.ак.В.И.Шумакова МЗ РФ

123182, ул. Щукинская, д. 1. Тел. (926) 651-40-64

Nadezda Koloskova

1, Shchukinskaya str., Moscow, 123182. Phone: (926) 651-40-64

nkrasotka@mail.ruХалилулинТ. А.KhalilulinT. A.

Тимур Абдулнаимович Халилулин

Москва

Moscow

timur-medicina@list.ruРябцевД. В.RyabtsevD. V.

Дмитрий Вадимович Рябцев

Москва

Moscow

dvryabtsev@gmail.comПопцовВ. Н.PoptsovV. N.

Виталий Николаевич Попцов

Москва

Moscow

poptsov_vit@mail.ruФГБУ Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова, Минздрав РоссииРоссияShumakov National Medical Research Center of Transplantology and Artificial OrgansRussian FederationФГБУ Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова, Минздрав России; ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова, Минздрав России (Сеченовский университет)РоссияShumakov National Medical Research Center of Transplantology and Artificial Organs; Sechenov UniversityRussian Federation2023080420232519098Copyright © Колоскова Н.Н., Халилулин Т.А., Рябцев Д.В., Попцов В.Н., 20232023Колоскова Н.Н., Халилулин Т.А., Рябцев Д.В., Попцов В.Н.Koloskova N.N., Khalilulin T.A., Ryabtsev D.V., Poptsov V.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1569

Хроническая сердечная недостаточность на фоне врожденных пороков сердца, преимущественно в раннем детском возрасте, или различных форм кардиомиопатий, чаще встречающихся в подростковом возрасте, представляет собой важную причину заболеваемости и смертности среди детского населения [1, 2]. Ввиду увеличения за последние два десятилетия количества пациентов, страдающих терминальной стадией хронической сердечной недостаточности, рефрактерной к медикаментозной терапии, и существующего дефицита донорских органов в педиатрической практике вопрос о применении длительной механической поддержки кровообращения становится все более актуальным. Ведение пациентов представляет собой мультидисциплинарную задачу, так как длительное применение антикоагулянтной и антитромбоцитарной терапии, направленной на предупреждение тромбоза искусственного желудочка сердца, имеет потенциально опасные, жизнеугрожающие осложнения, а именно острое нарушение мозгового кровообращения по геморрагическому типу и кровотечения различной степени тяжести.

Chronic heart failure (CHF) against the background of congenital heart disease, mostly in early childhood, or various forms of cardiomyopathies, more common in teenage age, represents an important cause of morbidity and mortality in the pediatric population [1, 2]. Due to the increase in the number of patients suffering from refractory end-stage CHF over the last two decades, and the current shortage of donor organs in pediatric practice, the issue of long-term mechanical circulatory support (MCS) is becoming increasingly a pressing problem. Patient management is a multidisciplinary task, since prolonged use of anticoagulant and antiplatelet therapy to prevent ventricular thrombosis has potentially life-threatening complications - acute hemorrhagic stroke and bleeding of varying severity.

сердечная недостаточность у детейдлительная механическая поддержка кровообращенияантикоагулянтная терапияантиагрегантная терапияheart failure in childrenlong-term mechanical circulatory supportanticoagulant therapyantiplatelet therapyReferencesMasarone D, Valente F, Rubino M, Vastarella R, Gra-vino R, Rea A et al. Pediatric Heart Failure: A Practical Guide to Diagnosis and Management. Pediatr Neonatol. 2017; 58 (2): 303-312.Daniele Masarone, Fabio Valente at al. Pediatric Heart Failure: A Practical Guide to Diagnosis and Management. Pediatrics & Neonatology. 2017; 58 (2): 303-312Rossano JW, Shaddy RE. Heart failure in children: etiology and treatment. JPediatr. 2014; 165 (2): 228-233.Rossano JW, Shaddy RE. Heart failure in children: etiology and treatment. J Pediatr 2014;165 (2): 228 – 233.Kreuziger LB, Massicotte MP. Adult and pediatric mechanical circulation: a guide for the hematologist. Hema-tol Am Soc Hematol Educ Program. 2018; 30: 507-515.Baumann Kreuziger L, Patricia Massicotte M. Adult and pediatric mechanical circulation: a guide for the hematologist. Hematol Am Soc Hematol Educ Program. 2018. 30:507–515.Owens WR, Bryant R 3rd, Dreyer WJ, Price JF, Morales DL. Initial Clinical Experience With the HeartMate II Ventricular Assist System in a Pediatric Institution. Artif Organs. 2010; 34: 600-603.Owens WR, Bryant R, Dreyer WJ, et al. Initial Clinical Experience With the HeartMate II Ventricular Assist System in a Pediatric Institution. Artif Organs 2010. 34:600-614D’Alessandro D, Forest SJ, Lamour J, Hsu D, Weinstein S, Goldstein D. First reported use of the Heartware HVAD in the US as bridge to transplant in an adolescent. Pediatr Transplantation. 2012; 16: 356-359.D’Alessandro D, Forest SJ, Lamour J, et al. First reported use of the Heartware HVAD in the US as bridge to transplant in an adolescent. Pediatr Transplantation 2012:16: 356- 359.Morales DLS, Adachi I, Peng DM, Sinha P, Lorts A, Fields K et al. Fourth Annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) Report. Ann Thorac Surg. 2020; 110 (6): 1819-1831.David L S Morales , Iki Adachi, David M Peng at al. Fourth Annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) Report. Ann Thorac Surg. 2020 110(6):1819-1831Ekdahl KN, Teramura Y, Hamad OA, Asif S, Duehr-kop C, Fromell K et al. Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation. Immunol Rev. 2016; 274 (1): 245-269.Ekdahl KN, Teramura Y, Hamad OA, et al. Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation. Immunol Rev. 2016;274(1): 245-269.Himmelreich G, Ullmann H, Riess H, Rosch R, LoebeM, Schiessler A, Hetzer R. Pathophysiologic role of contact activation in bleeding followed by thromboembolic complications after implantation of a ventricular assist device. ASAIO J. 1995; 41 (3): M790-M794.Himmelreich G, Ullmann H, Riess H, et al. Pathophysiologic role of contact activation in bleeding followed by thromboembolic complications after implantation of a ventricular assist device. ASAIO J. 1995; 41(3):M790-M794.Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI. Medical device-induced thrombosis: what causes it and how can we prevent it? J Thromb Haemost. 2015; 13 (suppl 1): S72-S81.Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI. Medical device-induced thrombosis: what causes it and how can we prevent it? J Thromb Haemost. 2015;13(suppl 1):S72-S81Monagle P, Barnes C, Ignjatovic V, Furmedge J, Ne-wall F, Chan A et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006; 95: 362-372.Monagle P, Barnes C, Ignjatovic V. at al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006. 95:362–72.Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P Development of the human coagulation system in the full-term infant. Blood. 1987; 70: 165-172.Andrew M Paes B, Milner R, Johnston M, Mitchell L, et al. Development of the human coagulation system in the full-term infant. Blood. (1987) 70:165–72.Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol. 1990; 12: 95-104.Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol. 1990. 12:95– 104.Williams GD, Bratton SL, Nielsen NJ, Ramamoorthy C. Fibrinolysis in pediatric patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1998; 12: 633-638.Williams GD, Bratton SL, Nielsen NJ, at al. Fibrinolysis in pediatric patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1998. 12:633–638.Kreuziger LB, Massicotte MP. Adult and pediatric mechanical circulation: a guide for the hematologist. Hematol Am Soc Hematol Educ Program. 2018; 30: 507-515.Baumann Kreuziger L, Patricia Massicotte M. Adult and pediatric mechanical circulation: a guide for the hematologist. Hematol Am Soc Hematol Educ Program. 2018. 30:507–515.Edmunds EL. The blood-surface interface. Gravlee GP, editor. Cardiopulmonary Bypass: Principles and Practice 3 ed. Philadelphia, PA: Lippincott Williams & Wilkins (2008).Edmunds EL. The blood -surface interface. In: Gravlee GP, editor. Cardiopulmonary Bypass: Principles and Practice 3 ed. Philadelphia, PA: Lippincott Williams & Wilkins (2008).Kreuziger LB, Massicotte MP. Mechanical circulatory support: balancing bleeding and clotting in high-risk patients. Hematol Am Soc Hematol Educ Program. 2015: 61-68.Baumann Kreuziger L, Massicotte MP. Mechanical circulatory support: balancing bleeding and clotting in high-risk patients. Hematology Am Soc Hematol Educ Program. 2015: 61– 68.Rosenthal DN, Almond CS, Jaquiss RD, Peyton CE, Auerbach SR, Morales DR et al. Adverse events in children implanted with ventricular assist devices in the United States: data from the pediatric interagency registry for mechanical circulatory support (PediMACS). J Heart Lung Transplant. 2016; 35: 569-577.Rosenthal DN, Almond C S, Jaquiss RD, et al. Adverse events in children implanted with ventricular assist devices in the United States: data from the pediatric interagency registry for mechanical circulatory support (PediMACS). J Heart Lung Transplant. 2016. 35:569–577.Sutor AH, Massicotte P, Leaker M, Andrew M. Heparin therapy in pediatric patients. Semin Thromb Hemost. 1997; 23: 303-319.Sutor AH, Massicotte P, Leaker M, Andrew M. Heparin therapy in pediatric patients. Semin Thromb Hemost. 1997. 23:303–319.Severin T, Sutor AH. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost. 2001; 27: 293-299.Severin T, Sutor AH. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost. 2001; 27:293–299.Vakil NH, Kanaan AO, Donovan JL. Heparin-Induced Thrombocytopenia in the Pediatric Population: A Review of Current Literature. J Pediatr Pharmacol Ther. 2012; 17 (1): 12-30.Niyati H. Vakil, Abir O. Kanaan, Jennifer L. Donovan Heparin-Induced Thrombocytopenia in the Pediatric Population: A Review of Current Literature. J Pediatr Pharmacol Ther. 2012; 17(1): 12–30.Avila L, Amiri N, Yenson P, Khan S, Zavareh ZT, Chan AKC et al. Heparin-Induced Thrombocytopenia in a Pediatric Population: Implications for Clinical Probability Scores and Testing. J Pediatr. 2020; 226: 167-172.Laura Avila, Nour Amiri, Paul Yenson. Heparin-Induced Thrombocytopenia in a Pediatric Population: Implications for Clinical Probability Scores and Testing. THE JOURNAL OF PEDIATRICS. 2020. 1: 167 -172Kishimoto TK, Viswanathan K, Ganguly T, Elankuma-ran S, Smith S, Pelzer K et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008; 358: 24572467.Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008; 358:2457– 2467.Bhandari M, Hirsh J, Weitz JI, Young E, Venner TJ, Shaughnessy SG. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost. 1998; 80: 413-417.Bhandari M, Hirsh J, Weitz JI, at al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost. 1998; 80:413–417.Jones AJ, O’Mara KL, Kelly BJ, Samraj RS. The impact of antithrombin III use in achieving anticoagulant goals in pediatric patients. J Pediatr Pharmacol Ther. 2017; 22: 320-325.Jones, AJ, O’Mara, KL, Kelly, BJ, Samraj, RS. The impact of antithrombin III use in achieving anticoagulant goals in pediatric patients. J Pediatr Pharmacol Ther. 2017;22:320-325.Buck ML. Bivalirudin as an alternative to heparin for anticoagulation in infants and children. J Pediatr Pharmacol Ther. 2015; 20: 408-417.Buck, ML. Bivalirudin as an alternative to heparin for anticoagulation in infants and children. J Pediatr Pharmacol Ther. 2015;20:408-417.Campbell CT, Diaz L, Kelly B. Description of Bivaliru-din Use for Anticoagulation in Pediatric Patients on Mechanical Circulatory Support. Ann Pharmacother. 2021; 55 (1): 59-64.Christopher T Campbell , Lucas Diaz , Brian Kelly . Description of Bivalirudin Use for Anticoagulation in Pediatric Patients on Mechanical Circulatory Support Ann Pharmacother. 2021;55(1):59-64.Ghbeis MB, Vander Pluym CJ, Thiagarajan RR. Hemostatic challenges in pediatric critical care medicine - hemostatic balance in VAD. FrontPediatr. 2021; 26: 625632.Ghbeis MB, Vander Pluym CJ, Thiagarajan RR. Hemostatic challenges in pediatric critical care medicine – hemostatic balance in VAD. Front Pediatr. 2021; 26:625 - 632Steiner ME, Bomgaars LR, Massicotte MP. Berlin heart EXCOR pediatric VAD IDE study investigators antithrombotic therapy in a prospective trial of a pediatric ventricular assist device. ASAIO J. 2016; 62: 719-727.Steiner ME, Bomgaars LR, Massicotte MP. Berlin heart EXCOR pediatric VAD IDE study investigators antithrombotic therapy in a prospective trial of a pediatric ventricular assist device. ASAIO J. (2016) 62:719– 27Sylvia LM, Ordway L, Pham DT, DeNofrio D, Kier-nan M. Bivalirudin for treatment of LVAD thrombosis: a case series. ASAIO J. 2014; 60: 744-747.Sylvia LM, Ordway L, Pham DT, at al. Bivalirudin for treatment of LVAD thrombosis: a case series. ASAIO J. (2014) 60:744– 7.VanderPluym CJ, Cantor RS, Machado D, Boyle G, May L, Griffiths E et al. Utilization and outcomes of children treated with direct thrombin inhibitors on pa-racorporeal ventricular assist device support. ASAIO J. 2020; 66: 939-945.VanderPluym CJ, Cantor RS, Machado D, et al. Utilization and outcomes of children treated with direct thrombin inhibitors on paracorporeal ventricular assist device support. ASAIO. (2020) 66:939– 45.Miera O, Schmitt KL, Akintuerk H, Boet A, Cesnjevar R, Chila T et al. Antithrombotic therapy in pediatric ventricular assist devices: Multicenter survey of the European EXCOR Pediatric Investigator Group. Int JArtif Organs. 2018 Jul; 41 (7): 385-392.Oliver Miera, Katharina L Schmitt, Hakan Akintuerk at al. Antithrombotic therapy in pediatric ventricular assist devices: Multicenter survey of the European EXCOR Pediatric Investigator Group. Int J Artif Organs 2018 Jul;41(7):385-392.Steiner ME, Bomgaars LR, Massicotte MP. Antithrombotic therapy in a prospective trial of a pediatric ventricular assist device. ASAIO J. 2016; 62: 719-27.Steiner ME, Bomgaars LR, Massicotte MP. Antithrombotic therapy in a prospective trial of a pediatric ventricular assist device. ASAIO J. (2016) 62:719–27.Peng E, KirkR, Wrightson N, Duong P, Ferguson L, Gri-selli M et al. An extended role of continuous flow device in pediatric mechanical circulatory support. Ann Thorac Surg. 2016; 102: 620-627.Peng E, Kirk R, Wrightson N, et al. An extended role of continuous flow device in pediatric mechanical circulatory support. Ann Thorac Surg. 2016;102:620–627Rosenthal DN, Lancaster CA, McElhinney DB, Chen S, Stein M, Lin A et al. Impact of a modified antithrombotic guideline on stroke in children supported with a pediatric ventricular assist device. J Heart Lung Transplant. 2017; 36: 1250-1257.Rosenthal DN, Lancaster CA, Mc Elhiney DB, et al. Impact of a modified antithrombotic guideline on stroke in children supported with a pediatric ventricular assist device. J Heart Lung Transplant. (2017) 36:1250–7.O’Connor MJ, Lorts A, Davies RR, Fynn-Thompson F, Joong A, Maeda K et al. Early experience with the Heart-Mate 3 continuousflow ventricular assist device in pediatric patients and patients with congenital heart disease: A multicenter registry analysis. J Heart Lung Transplant. 2020 Jun; 39 (6): 573-579.Matthew J. O’Connor, Angela Lorts, Ryan R. Davies. Early experience with the HeartMate 3 continuousflow ventricular assist device in pediatric patients and patients with congenital heart disease: A multicenter registry analysis. J Heart Lung Transplant 2020 Jun;39(6):573-579.Andreas M, Moayedifar R, Wieselthaler G, Wolzt M, Riebandt J, Haberl T et al. Increased thromboembolic events with dabigatran compared with Vitamin K antagonism in left ventricular assist device patients. Circ Heart Fail. 2017; 10 (5): 1-6.Andreas M, Moayedifar R, Wieselthaler G, et al. Increased thromboembolic events with dabigatran compared with Vitamin K antagonism in left ventricular assist device patients. Circulation Hear Fail 2017. 10(5): 1-6Parikh V, Parikh U, Ramirez AM, Lamba H, George J, Fedson S et al. Novel oral anticoagulants in patients with continuous flow left ventricular assist devices. J Heart Lung Transplant. 2019; 38: S425.Parikh V, Parikh U, Ramirez AM, et al.. Novel oral anticoagulants in patients with continuous flow left ventricular assist devices. J Heart Lung Transplant. 2019; 38:S425Schulte-Eistrup S, Mayer-Wingert N, Reiss N, Sinder-mann J, Warnecke H. Apixaban in HVAD patients noncompliant to standard vitamin-k-antagonism. J Heart Lung Transplant. 2019; 38: S68.Schulte-Eistrup S, Mayer-Wingert N, Reiss N, at al. Apixaban in HVAD patients non-compliant to standard vitamin-k-antagonism.J Heart Lung Transplant. 2019; 38:S68Li S, Mahr C. Anticoagulation in the HeartMate 3 Left Ventricular Assist Device: Are We Finally Moving the Needle? ASAIO J. 2022; 68 (3): 323-324.Li, Song*; Mahr Claudius. Anticoagulation in the HeartMate 3 Left Ventricular Assist Device: Are We Finally Moving the Needle? * ASAIO Journal: 2022. 68 (3): 323-324Ghbeis MB, Vander Pluym CJ, Thiagarajan RR. Hemostatic Challenges in Pediatric Critical Care Medicine -Hemostatic Balance in VAD. Front Pediatr. 2021; 9: 1-11.Muhammad Bakr Ghbeis, Christina J Vander Pluym, Ravi Ram Thiagarajan. Hemostatic Challenges in Pediatric Critical Care Medicine—Hemostatic Balance in VAD Front. Pediatr., 2021. 9: 1- 11.

The authors declare that there are no conflicts of interest present.